Enhanced glutamatergic transmission reduces the anticonvulsant potential of lamotrigine but not of felbamate against tonic-clonic seizures.
Tomasz Tomczyk, Grzegorz Haberek, Beata Zuchora, Agata Jarosławska-Zych, Mieczysław S Kowalczyk, Marian Wielosz, Ewa M Urbańska
文献索引:Pharmacol. Rep. 59(4) , 462-6, (2007)
全文:HTML全文
摘要
The efficacy of lamotrigine and felbamate against maximal electroshock (MES)-induced seizures was assessed under conditions mimicking the pharmacoresistance associated with an increased excitatory neurotransmission. N-methyl-D-aspartate (NMDA), but not kainate applied at subconvulsive dose, reduced the activity of lamotrigine against MES-induced seizures increasing its ED50 value from 4.3 (3.2-5.6) to 6.1 (5.2-7.2) mg/kg (p < 0.001). This effect was reversed by co-application of an NMDAreceptor antagonist D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 40116) at 0.1 mg/kg [4.5 (3.7-5.6) vs. 6.1 (5.2-7.2) mg/kg; p < 0.001]. The anticonvulsive action of felbamate was altered by neither NMDAnor kainate. In conclusion, the data presented here indicate that felbamate, but not lamotrigine, effectively prevents generalized tonic-clonic seizures, also when NMDA-mediated neurotransmission is enhanced. The impaired antiepileptic potential of lamotrigine might be restored in such scenario by the co-administration of a very low dose of NMDA receptor antagonist.
相关化合物
相关文献:
2003-05-01
[Kidney Int. 63(5) , 1764-75, (2003)]
2005-02-15
[Physiol. Behav. 84(2) , 251-64, (2005)]
2004-01-01
[Pol. J. Pharmacol. 56(1) , 59-66, (2004)]
1990-01-01
[Prog. Clin. Biol. Res. 361 , 421-7, (1990)]
2008-01-01
[Pharmacol. Rep. 60(5) , 655-63, (2008)]